Nuvation Bio (NUVB) to Release Earnings on Thursday

Nuvation Bio (NYSE:NUVB) will likely be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Nuvation Bio to post earnings of ($0.14) per share for the quarter.

Nuvation Bio Stock Performance

Shares of NUVB opened at $1.97 on Thursday. Nuvation Bio has a twelve month low of $1.67 and a twelve month high of $4.16. The firm’s 50 day moving average price is $2.53 and its two-hundred day moving average price is $2.63. The firm has a market cap of $663.04 million, a P/E ratio of -0.91 and a beta of 1.45.

Analyst Upgrades and Downgrades

Several analysts have issued reports on NUVB shares. HC Wainwright upped their price target on shares of Nuvation Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Wedbush reaffirmed an “outperform” rating and set a $5.00 price target on shares of Nuvation Bio in a research report on Monday, January 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Nuvation Bio presently has an average rating of “Buy” and a consensus target price of $8.20.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.